Retrophin is focused on finding and developing treatments for conditions with specific characteristics, including those: (1) that are debilitating and often lethal, with a high cost to the system and patient, and where patients experience a low quality of life; (2) that are well understood, with scientific consensus regarding the cause; and (3) for which we believe the development timeline will be rapid.
|Product/Program||Pre-Clinical||Phase 1||Phase 2||Phase 3||Commercial|
|Focal Segmental Glomerulosclerosis:|
|Pantothenate Kinase Associated Neurodegeneration:|
|Duchenne Muscular Dystrophy:|
|Spinal Muscular Atrophy:|